BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 15684491)

  • 21. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
    Ling SY; Huizinga RB; Mayo PR; Larouche R; Freitag DG; Aspeslet LJ; Foster RT
    Br J Clin Pharmacol; 2014 Jun; 77(6):1039-50. PubMed ID: 24330024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
    Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
    Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
    Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
    Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
    Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
    Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implication of CYP 3A in the toxicity of cyclosporin G (CsG), cyclosporin A (CsA) and FK506 on rat hepatocytes in primary culture.
    Ellouk-Achard S; Martin C; Pham-Huy C; Duc HT; Thevenin M; Dutertre-Catella H; Warnet JM; Claude JR
    Arch Toxicol; 1997; 71(7):437-42. PubMed ID: 9209689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
    Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
    Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can oral midazolam predict oral cyclosporine disposition?
    Paine MF; Davis CL; Shen DD; Marsh CL; Raisys VA; Thummel KE
    Eur J Pharm Sci; 2000 Nov; 12(1):51-62. PubMed ID: 11121733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
    J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclosporin A-induced free radical generation is not mediated by cytochrome P-450.
    Krauskopf A; Buetler TM; Nguyen NS; Macé K; Ruegg UT
    Br J Pharmacol; 2002 Feb; 135(4):977-86. PubMed ID: 11861326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats.
    Konishi H; Sumi M; Shibata N; Takada K; Minouchi T; Yamaji A
    J Pharm Pharmacol; 2004 Apr; 56(4):477-83. PubMed ID: 15099443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone.
    Yokogawa K; Shimada T; Higashi Y; Itoh Y; Masue T; Ishizaki J; Asahi M; Miyamoto K
    Biochem Pharmacol; 2002 Feb; 63(4):777-83. PubMed ID: 11992648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glycyrrhizin accelerates the metabolism of triptolide through induction of CYP3A in rats.
    Tai T; Huang X; Su Y; Ji J; Su Y; Jiang Z; Zhang L
    J Ethnopharmacol; 2014 Mar; 152(2):358-63. PubMed ID: 24486211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capsaicin pretreatment increased the bioavailability of cyclosporin in rats: involvement of P-glycoprotein and CYP 3A inhibition.
    Zhai XJ; Shi F; Chen F; Lu YN
    Food Chem Toxicol; 2013 Dec; 62():323-8. PubMed ID: 24013073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
    Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
    J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic interaction between cyclosporine and sirolimus.
    Bai S; Stepkowski SM; Kahan BD; Brunner LJ
    Transplantation; 2004 May; 77(10):1507-12. PubMed ID: 15239612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.
    Fukushima K; Haraya K; Terasaka S; Ito Y; Sugioka N; Takada K
    Biol Pharm Bull; 2008 Jun; 31(6):1209-14. PubMed ID: 18520056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats.
    Shibata N; Kageyama M; Kimura K; Tadano J; Hukushima H; Namiki H; Yoshikawa Y; Takada K
    Biol Pharm Bull; 2004 Feb; 27(2):203-9. PubMed ID: 14758034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats.
    Machavaram KK; Gundu J; Yamsani MR
    Pharmazie; 2004 Dec; 59(12):957-60. PubMed ID: 15638086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells.
    Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M
    J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.